Abstract
The use of mineralocorticoid receptor antagonists for the prevention of anthracycline-induced cardiotoxicity is controversial and lacks evidence. The aim of this study is to evaluate the effect of spironolactone in the primary prevention of cardiotoxicity in cancer patients undergoing chemotherapy with anthracycline within 12 months. Methods: Randomized, double-blind, single-center, place…